Archives of Dermatological Research

, Volume 300, Issue 6, pp 297–301 | Cite as

Interferon-β therapy for malignant melanoma: the dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells

  • Hitomi Kubo
  • Atsuko Ashida
  • Kazuhiko MatsumotoEmail author
  • Toshiro Kageshita
  • Akifumi Yamamoto
  • Toshiaki Saida
Original Paper


We investigated the anti-tumor effect of human interferon-β (HuIFN-β) against malignant melanoma. In vitro study revealed that HuIFN-β not only inhibited proliferation of melanoma cells (seven cell lines: MM-AN, MM-BP, MM-LH, MM-RU, PM-WK, RPM-EP, RPM-MC) but also induced apoptosis in a dose dependent fashion, though the sensitivity to HuIFN-β was different among cell lines. In addition, we administered HuIFN-β into cutaneous metastatic lesions of melanoma and evaluated clinical and histopathological effects. Although the size of the metastatic cutaneous lesion did not change by the intralesional injection of HuIFN-β, histopathological examination revealed apoptotic changes of melanoma cells along with dense lymphohistiocytic infiltration. The present study confirmed direct and indirect inhibitory effects of HuIFN-β on human melanoma cells and suggests that local higher concentration of HuIFN-β is needed to eradicate melanoma lesions.


Interferon(IFN)-β Human melanoma cell Apoptosis Growth inhibition 



This study was supported in part by the Grant-in-Aid for Cancer Research (15–10) from the Ministry of Health, Labor and Welfare of Japan and the Grant-in-Aid for Scientific Research from the Japanese Society for the Promotion of Science, Tokyo. We thank Ryo Ogawa for his excellent technical assistance.


  1. 1.
    Albini A, Marchisone C, Del Grosso F, Benelli R, Masiello L, Tacchetti C et al (2000) Inhibition of angiogenesis and vascular tumor growth by interferon producing cells: A gene therapy approach. Am J Pathol 156:1381–1393PubMedGoogle Scholar
  2. 2.
    Byers HR, Etoh T, Doherty RJ, Sober JA, Mihm CM Jr (1991) Cell migration and actin organization in cultured human primary, reccurent cutaneous and metastatic melanoma. Am J Pathol 139:423–435PubMedGoogle Scholar
  3. 3.
    Chawla-Sarkar M, Leaman DW, Borden EC (2001) Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2. Clin Cancer Res 7:1821–1831PubMedGoogle Scholar
  4. 4.
    Chawla-Sarkar M, Leaman DW, Jacobs BS, Borden EC (2002) IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-indeced apoptosis. J Immunol 169:847–855PubMedGoogle Scholar
  5. 5.
    Deiss LP, Feinstein E, Berissi H, Cohen O, Kimchi A (1995) Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. Genes Dev 9:15–30PubMedCrossRefGoogle Scholar
  6. 6.
    Dong Z, Greene G, Pettaway C, Dinney CP, Eue I, Lu W et al (1999) Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta. Cancer Res 59:872–879PubMedGoogle Scholar
  7. 7.
    Garbe C, Krasagakis K, Zouboulis CC, Schroder K, Kruger S, Stadler R et al (1990) Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype. J Invest Dermatol 95:231s–237sPubMedCrossRefGoogle Scholar
  8. 8.
    Garbe C (1993) Chomotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res 3:291–299PubMedGoogle Scholar
  9. 9.
    Hong YK, Chung DS, Joe YA, Yang YJ, Kim KM, Park YS et al (2000) Efficient inhibition in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development. Clin Cancer Res 6:3354–3360PubMedGoogle Scholar
  10. 10.
    Horikoshi T, Fukuzawa K, Hanada N, Ezoe K, Eguchi H, Hamaoka S et al (1995) In vitro comparative study of the antitumor effects of human interferon-alpha, beta, and gamma on the growth and invasive potential of human melanoma cells. J Dermatol 22:631–636PubMedGoogle Scholar
  11. 11.
    Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW (1992) Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon β. J Natl Cancer Inst 84(15):1185–1190PubMedCrossRefGoogle Scholar
  12. 12.
    Kikuchi K, Nakagawa H, Kondo T, Etoh T, Byers HR, Mihm CM Jr et al (1996) Decreased ETB receptor expression in human metastatic melanoma cells. Biochem Biophys Res Commun 219:734–739PubMedCrossRefGoogle Scholar
  13. 13.
    Kopf I, Hanson C, Delle U, Weimarck A, Stierner U (1996) Action of interferon alpha and beta on four human melanoma cell lines in vitro. Anticancer Res 16(2):791–798PubMedGoogle Scholar
  14. 14.
    Liu T, Biddle D, Hanks AN, Brouha B, Yan H, Lee RM et al (2006) Activation of dual apoptotic pathways in human melanocytes and protection by Survivin. J Invest Dermatol 126:2247–2256PubMedCrossRefGoogle Scholar
  15. 15.
    Nagatani T, Ichiyama S, Onuma R, Miyazawa M, Matsuzaki T, Miyagawa K et al (1995) The use of DAV (DTIC, ACNU and VCR) and natural interferon-beta combination therapy in malignant melanoma. Acta Derm Venerol 75:494PubMedGoogle Scholar
  16. 16.
    Qin X Q, Runkel L, Deck C, DeDios C, Barsoum J (1997) Interferon-beta induces S phase accumulation selectively in human transformed cells. J Interferon Cytokine Res 17:355–367PubMedCrossRefGoogle Scholar
  17. 17.
    Stark GR, Kerr IM, Williams BRG, Silverman RH, Schreiber RD (1998) How cells respond to interferons. Annu Rev Biochem 67:227–264PubMedCrossRefGoogle Scholar
  18. 18.
    von Stamm U, Brocker EB, von Depka Prondzinski M, Ruiter DJ, Rumke P, Broding C et al (1993) Effects of systemic interferon-alpha(IFN-alpha) on the antigenic phenotype of melanoma metastases. EORTC Melanoma Group Cooperative Study No. 18852. Melanoma Res 3:173–180CrossRefGoogle Scholar
  19. 19.
    Zhang H, Koty PP, Mayotte J, Levitt ML (1999) Induction of multiple programmed cell death pathways by IFN-beta in human non-small-cell lung cancer cell lines. Exp Cell Res 247:133–141PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Hitomi Kubo
    • 1
  • Atsuko Ashida
    • 1
  • Kazuhiko Matsumoto
    • 1
    • 2
    Email author
  • Toshiro Kageshita
    • 3
  • Akifumi Yamamoto
    • 4
  • Toshiaki Saida
    • 1
  1. 1.Department of DermatologyShinshu University School of MedicineMatsumotoJapan
  2. 2.Clinical Trial Research CenterShinshu University HospitalMatsumotoJapan
  3. 3.Department of DermatologyKumamoto University School of MedicineKumamotoJapan
  4. 4.Department of Skin Oncology, International Medical CenterSaitama Medical UniversityHidakaJapan

Personalised recommendations